Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.1K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.1K
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.7K
Clinical Trials01:16

Clinical Trials

9.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
9.5K
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

14
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
14
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

825
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
825
Pharmacovigilance01:19

Pharmacovigilance

1.0K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Elinzanetant for the Treatment of Menopausal Hot Flashes: A Plain Language Review of the OASIS-1-4 Clinical Trial Results.

Women's health (London, England)·2026
Same author

Optimizing estradiol serum levels for optimal skeletal and cardiovascular health during transdermal menopausal hormone therapy.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·2026
Same author

Nocturia in postmenopausal women.

Menopause (New York, N.Y.)·2026
Same author

A Contemporary View of Menopausal Hormone Therapy: Correction.

Obstetrics and gynecology·2026
Same author

Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Quantification of "Mercy Sex" in Heterosexual Women.

Journal of sex & marital therapy·2026

Related Experiment Video

Updated: Oct 4, 2025

Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues
08:07

Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues

Published on: April 7, 2023

3.7K

Safety Profile of Bremelanotide Across the Clinical Development Program.

Anita H Clayton1, Sheryl A Kingsberg2, David Portman3

  • 1Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, Virginia, USA.

Journal of Women'S Health (2002)
|February 11, 2022
PubMed
Summary

Bremelanotide is FDA-approved for hypoactive sexual desire disorder. Its safety profile shows common mild side effects like nausea and flushing, with rare serious events. Caution is advised for cardiovascular risks.

Keywords:
bremelanotidehypoactive sexual desire disorderpremenopausal

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.6K
A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

12.6K

Related Experiment Videos

Last Updated: Oct 4, 2025

Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues
08:07

Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues

Published on: April 7, 2023

3.7K
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.6K
A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

12.6K

Area of Science:

  • Pharmacology
  • Clinical Trials
  • Women's Health

Background:

  • Bremelanotide is a melanocortin receptor agonist approved by the FDA.
  • It treats premenopausal women with acquired, generalized hypoactive sexual desire disorder.
  • This review examines bremelanotide's safety profile from its clinical development program.

Purpose of the Study:

  • To review the safety profile of bremelanotide.
  • To analyze adverse events (AEs) and drug interactions from clinical trials.
  • To provide recommendations for bremelanotide use in specific patient populations.

Main Methods:

  • The review encompasses data from 3500 subjects across 43 studies (Phases 1-3).
  • Phase 3 studies involved up to 18 months of bremelanotide treatment.
  • Data from integrated double-blind and open-label phases of Phase 3 studies were analyzed.

Main Results:

  • Most common AEs: nausea (40.0%), flushing (20.3%), headache (11.3%), injection site reactions (5.4%).
  • Nausea was the primary reason for discontinuation. Serious AEs were rare; no deaths occurred.
  • Transient blood pressure increases and rare focal hyperpigmentation were noted. Clinically significant drug interactions were limited.

Conclusions:

  • Bremelanotide's adverse events are generally mild to moderate.
  • Use with caution in patients with cardiovascular disease risk factors.
  • Ensure blood pressure is well-controlled during bremelanotide treatment.